Role of the C-terminal linear region of EGF-like growth factors in ErbB specificity

References

• Ballinger MD, Jones JT, Lofgren JA, Fairbrother WJ, Akita RW, Sliwkowski MX, Wells JA. Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display. J Biol Chem 1998; 273(19)11675–11684
   Google Scholar
• Berger MB, Mendrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004; 569(1–3)332–336
   Web of Science ®Google Scholar
• Campbell ID, Baron M, Cooke RM, Dudgeon TJ, Fallon A, Harvey TS, Tappin MJ. Structure–function relationships in epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha). Biochem Pharmacol 1990; 40(1)35–40
   Google Scholar
• Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110(6)763–773
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 1997; 16(7)1647–1655
   PubMed Web of Science ®Google Scholar
• Hobbs SS, Gallo RM, Riese DJ, Jr. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*. Growth Factors 2005; 23(4)273–283
   Web of Science ®Google Scholar
• Hommel U, Harvey TS, Driscoll PC, Campbell ID. Human epidermal growth factor. High resolution solution structure and comparison with human transforming growth factor alpha. J Mol Biol 1992; 227(1)271–282
   Google Scholar
• Hooft RW, Vriend G, Sander C, Abola EE. Errors in protein structures. Nature 1996; 381(6580)272
   PubMed Web of Science ®Google Scholar
• Jones JT, Ballinger MD, Pisacane PI, Lofgren JA, Fitzpatrick VD, Fairbrother WJ, Wells JA, Sliwkowski MX. Binding interaction of the heregulinbeta EGF domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis. J Biol Chem 1998; 273(19)11667–11674
   Google Scholar
• Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Lett 1999; 447(2–3)227–231
   PubMed Web of Science ®Google Scholar
• Jorissen RN, Epa VC, Treutlein HR, Garrett TP, Ward CW, Burgess AW. Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor. Protein Sci 2000; 9(2)310–324
   Google Scholar
• Kienhuis CB, Heuvel JJ, Ross HA, Swinkels LM, Foekens JA, Benraad TJ. Six methods for direct radioiodination of mouse epidermal growth factor compared: Effect of nonequivalence in binding behavior between labeled and unlabeled ligand. Clin Chem 1991; 37((10 Pt 1)1749–1755
   Google Scholar
• Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G. Making optimal use of empirical energy functions: Force-field parameterization in crystal space. Proteins 2004; 57(4)678–683
   PubMed Web of Science ®Google Scholar
• Lenferink AE, Kramer RH, van Vugt MJ, Konigswieser M, Di Fiore PP, van Zoelen EJ, van de Poll ML. Superagonistic behaviour of epidermal growth factor/transforming growth factor-alpha chimaeras: Correlation with receptor routing after ligand-induced internalization. Biochem J 1997; 327(Pt 3)859–865
   Google Scholar
• Luo C, Xu L, Zheng S, Luo X, Shen J, Jiang H, Liu X, Zhou M. Computational analysis of molecular basis of 1:1 interactions of NRG-1beta wild-type and variants with ErbB3 and ErbB4. Proteins 2005; 59(4)742–756
   Google Scholar
• Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110(6)775–787
   PubMed Web of Science ®Google Scholar
• Sato K, Nakamura T, Mizuguchi M, Miura K, Tada M, Aizawa T, Gomi T, Miyamoto K, Kawano K. Solution structure of epiregulin and the effect of its C-terminal domain for receptor binding affinity. FEBS Lett 2003; 553(3)232–238
   Google Scholar
• Stein RA, Staros JV. Evolutionary analysis of the ErbB receptor and ligand families. J Mol Evol 2000; 50(5)397–412
   PubMed Web of Science ®Google Scholar
• Stortelers C, van De Poll ML, Lenferink AE, Gadellaa MM, van Zoelen C, van Zoelen EJ. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers. Biochemistry 2002; 41(13)4292–4301
   Google Scholar
• Stortelers C, van der Woning SP, Jacobs-Oomen S, Wingens M, van Zoelen EJ. Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands. J Biol Chem 2003; 278(14)12055–12063
   Google Scholar
• van de Poll ML, van Rotterdam W, Gadellaa MM, Jacobs-Oomen S, van Zoelen EJ. Ligand depletion negatively controls the mitogenic activity of epidermal growth factor. Exp Cell Res 2005; 304(2)630–641
   Google Scholar
• van der Burg B, Rutteman GR, Blankenstein MA, de Laat SW, van Zoelen EJ. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: Synergistic action of insulin and estrogen. J Cell Physiol 1988; 134(1)101–108
   Google Scholar
• van der Woning SP, van Rotterdam W, Nabuurs SB, Venselaar H, Jacobs-Oomen S, Wingens M, Vriend G, Stortelers C, van Zoelen EJ. Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands. J Biol Chem 2006; 281(52)40033–40040
   Google Scholar
• Vriend G. WHAT IF: A molecular modeling and drug design program. J Mol Graph 1990; 8(1)52–56, 29
   PubMedGoogle Scholar
• Wingens M, Jacobs-Oomen S, van der Woning SP, Stortelers C, van Zoelen EJ. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3. Biochemistry 2006; 45(14)4703–4710
   Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2(2)127–137
   PubMed Web of Science ®Google Scholar